European Union - English - EMA (European Medicines Agency)

biopartners gmbh - somatropin - growth - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropin biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (ghd).adult-onset: patients with ghd in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a ghd.childhood-onset: in patients with childhood-onset isolated ghd (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-i (igf-i) concentrations (< -2 standard-deviation score (sds)), who may be considered for one test. the cut-off point of the dynamic test should be strict.

Canada - English - Health Canada

hoffmann-la roche limited - vemurafenib - tablet - 240mg - vemurafenib 240mg - antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - vemurafenib - tablet - 240mg

European Union - English - EMA (European Medicines Agency)

dr. friedrich eberth arzneimittel gmbh - lasofoxifene tartrate - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).when determining the choice of fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - vemurafenib - melanoma - antineoplastic agents - vemurafenib is indicated in monotherapy for the treatment of adult patients with braf-v600-mutation-positive unresectable or metastatic melanoma.,

Canada - English - Health Canada

sandoz canada incorporated - cyclosporine - capsule - 25mg - cyclosporine 25mg - immunosuppressive agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - pazopanib (pazopanib hydrochloride) - tablet - 200mg - pazopanib (pazopanib hydrochloride) 200mg - antineoplastic agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - pazopanib (pazopanib hydrochloride) - tablet - 400mg - pazopanib (pazopanib hydrochloride) 400mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vemurafenib, quantity: 800 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; magnesium stearate; iron oxide red; hyprolose; purified talc; polyvinyl alcohol; macrogol 3350 - zelboraf is indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for a braf v600 mutation.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

theramex hq uk ltd - estradiol - transdermal patch - 50microgram/24hour